Curt Littler, M.D., StemCutis’ Advisory Board. A practicing dermatologist at SHARP Rees-Stealy Medical Group’s Division of Dermatology and Cutaneous Surgery, and before that at Scripps Clinic and Research Foundation’s Division of Dermatology and Cutaneous Surgery, Dr. Littler has contributed to >20 published papers in books and journals and >15 clinical studies as principal investigator or co-investigator. Active member of the American Academy of Dermatology, the American Medical Association and the American Society for Laser Medicine and Surgery.
“I looked at the photos [on StemCutis website] and actually was fairly impressed with results. The lines had a significant decrease in depth both using the photographic instrument and to the naked eye, the latter being the more important measure to the consumer. As I mentioned…, I like the patch because it makes a lot of sense to me (I believe it will to other MDs as well) and I definitely think it will be a good product for StemCutis.” – Curt Littler, MD
Neal Matheson, Former Chief Technology Officer (CTO) for the Johnson & Johnson Family of Consumer Companies.
Mr. Matheson spent 13 years (1994-2007) with J&J, where he helped achieve consistent above-market growth by introducing innovations across the portfolio. In particular, his contributions helped grow the J&J Skin Care category from a relatively small business into a multi-billion dollar leader. Between 2007 and 2012, he was CTO and Head of the New Businesses Unit at Unilever (London). His primary focus was to deliver new technologies to accelerate growth. He returned to J&J in July 2012, and helped to map the path forward for the global R&D function as it embarked on a new course, driving growth and high-value innovation.
“The StemCutis skin care line leverages learning from stem cells science to create unique formulations of cosmetic products. Growth factors, from safe/healthy progenitor cells, help rejuvenate the appearance of skin giving it smoothness, firmness and an even, healthy glow. Proprietary formulas assure potency and stability and appeal is enhanced by unique packaging. Overall, new products worth trying.” – Neal Matheson.
Ronald Wheeland, MD, FACP, Consultant in Laser Technology and Skin Cancer and StemCutis Board Member. Former president of the American Academy of Dermatology, the American Society for Dermatologic Surgery and the American Society for Laser Medicine and Surgery, he was previously professor and chief of the Division of Dermatology at the University of Arizona College of Medicine. He has authored > 250 publications, 68 book chapters, 8 textbook and numerous peer-reviewed articles. He is medical co-editor of Dermatology Times and sits on the editorial boards of “Journal of Drugs in Dermatology,” “Dermatologic Surgery,” “American Journal of Clinical Dermatology” and “Lasers in Surgery and Medicine.”